High Growth Tech Stocks In US With Potential For Expansion
The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.
Name
Revenue Growth
Earnings Growth
Growth Rating
Super Micro Computer
20.44%
29.79%
★★★★★★
Arcutis Biotherapeutics
25.76%
58.17%
★★★★★★
TG Therapeutics
26.03%
37.60%
★★★★★★
Alkami Technology
20.46%
85.16%
★★★★★★
Travere Therapeutics
28.65%
65.75%
★★★★★★
Alnylam Pharmaceuticals
22.74%
58.77%
★★★★★★
TKO Group Holdings
22.48%
25.17%
★★★★★★
AVITA Medical
28.22%
55.77%
★★★★★★
Lumentum Holdings
21.61%
120.49%
★★★★★★
Ascendis Pharma
32.36%
59.79%
★★★★★★
Click here to see the full list of 232 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Simply Wall St Growth Rating: ★★★★★★
Overview: Alnylam Pharmaceuticals, Inc. focuses on discovering, developing, and commercializing therapeutics based on ribonucleic acid interference with a market cap of approximately $30.78 billion.
Operations: Alnylam generates revenue primarily from the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.25 billion. The company operates within the biotechnology sector with a focus on innovative therapeutic solutions.
Alnylam Pharmaceuticals has demonstrated a robust commitment to innovation, particularly through its recent FDA approval of AMVUTTRA for ATTR-CM and Qfitlia for hemophilia. These approvals not only enhance its product portfolio but also underscore its R&D capabilities, reflected in a significant 22.7% annual revenue growth. The company's strategic presentations at various healthcare conferences, coupled with the launch of groundbreaking RNAi therapeutics like vutrisiran, show a clear trajectory towards addressing critical unmet medical needs. Despite being unprofitable currently, Alnylam's projected earnings growth of 58.77% annually suggests potential for future profitability and leadership in the biotech sector.
Navigate through the intricacies of Alnylam Pharmaceuticals with our comprehensive health report here.
Examine Alnylam Pharmaceuticals' past performance report to understand how it has performed in the past.
Simply Wall St Growth Rating: ★★★★★★
Overview: Ascendis Pharma A/S is a biopharmaceutical company specializing in the development of TransCon-based therapies for unmet medical needs across Denmark, Europe, North America, and globally, with a market cap of approximately $9.04 billion.
Operations: Ascendis Pharma generates revenue primarily from its biotechnology segment, amounting to €363.64 million. The company is focused on developing TransCon-based therapies to address unmet medical needs across various regions.
Ascendis Pharma is navigating a transformative phase with its recent NDA submission for TransCon CNP, targeting achondroplasia treatment, reflecting its commitment to addressing rare diseases through innovative drug development. Despite being unprofitable, the company's revenue is projected to grow at 32.4% annually, outpacing the US market average of 8.3%. With R&D expenses aligning closely with these ambitious projects, Ascendis also announced a share repurchase program valued at $18.25 million, signaling confidence in its future financial health. This strategic mix of product development and financial maneuvers positions Ascendis uniquely within the biotech landscape as it transitions towards profitability forecasted with an impressive annual earnings growth rate of 59.79%.
Get an in-depth perspective on Ascendis Pharma's performance by reading our health report here.
Explore historical data to track Ascendis Pharma's performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Natera, Inc. is a diagnostics company that offers molecular testing services globally, with a market cap of approximately $20.01 billion.
Operations: The company generates revenue primarily from the development and commercialization of molecular testing services, totaling approximately $1.70 billion.
Natera, a player in the genetic testing and diagnostics sector, is steering through a dynamic phase marked by strategic board expansions and intriguing clinical trials. With a revenue leap to $1.87 billion forecasted for 2025, the company's financial trajectory reflects vigorous growth, notably outpacing broader market trends. Recent R&D initiatives like the HEROES trial underscore Natera's commitment to pioneering in oncological research, potentially reshaping therapeutic approaches in cancer care. Moreover, the adoption of its Signatera test for Medicare coverage marks a significant milestone, enhancing its standing in precision medicine and boosting its commercial prospects amidst competitive pressures.
Unlock comprehensive insights into our analysis of Natera stock in this health report.
Review our historical performance report to gain insights into Natera's's past performance.
Embark on your investment journey to our 232 US High Growth Tech and AI Stocks selection here.
Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NasdaqGS:ALNY NasdaqGS:ASND and NasdaqGS:NTRA.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Evri to hire thousands more couriers after deal with DHL
Evri is set to expand its courier network with a recruitment drive for 5,000 new couriers, as the company looks to compete in the business letter market. The Yorkshire-based parcel firm recently announced a collaboration with DHL's UK ecommerce division, creating one of the UK's largest delivery networks. The addition of these new roles will bring Evri's total number of self-employed couriers to 33,000. These positions will be available across the UK, with a focus on areas such as Plymouth, Bury, Hastings, Dover, and Scarborough. Approximately 1,000 of the new jobs will be permanent, while the remainder will be flexible roles designed to accommodate the increased demand during the summer and other peak delivery periods. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Evri to hire 5,000 more couriers after agreeing DHL tie-up
Evri is planning to hire 5,000 couriers in a fresh recruitment drive as the parcel giant takes on rivals after entering the business letter market. The Yorkshire-based firm recently announced it was joining forces with DHL's UK ecommerce arm to form one of the country's biggest delivery firms. It said the new roles would bring its total self-employed courier network to 33,000, its highest number. The roles will be available throughout the UK, with a focus on regions including Plymouth, Bury, Hastings, Dover and Scarborough. About 1,000 of the new jobs will be permanent, while the rest are set to be flexible positions to cater to the typically busy summer months and other peak periods for deliveries. Couriers who commit to working five or more days a week, including Saturday and Sunday, are also given the chance to opt in to its revamped 'Evri Plus' scheme, which includes paid holiday and automatic enrolment into a pension scheme. Evri, which was previously part of the Hermes parcel group, was bought by US private equity firm Apollo for around £2.7 billion last year. It announced plans last month to merge with rival DHL's UK ecommerce business to create a combined company set to deliver more than one billion parcels and one billion letters each year. The deal means Evri will enter the UK business letter market for the first time, bolstering its competition to Royal Mail. Evri has spent £32 million on improving its customer service offering and has seen an improvement in its ratings over recent years, but has said there is 'more to do' to improve with customers continuing to report delivery issues. Chief executive Martijn de Lange said: 'We know that service, reliability and quality are critical factors for our clients and consumers, and so by expanding our self-employed network further, we remain focused on delivering in each of those areas.' Couriers typically earn about £20.90 an hour on average, according to Evri.
